All News

To the extent that some factors are modifiable, the takeaway for clinicians is to encourage their patients with multiple sclerosis (MS) to adopt healthy habits.

The drug, mastinib, reduced the chance of a confirmed disability progression by 37% in phase 2b/3 study results.

With more multiple sclerosis (MS) treatments becoming available, it is now possible to better personalize approaches, explained speakers during a session at MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

It is well known that women are disproportionately affected by multiple sclerosis (MS), but there remains a lack of understanding regarding gender differences in response to treatments for MS, said Riley Bove, MD, assistant professor of neurology at the UCSF Weill Institute for Neurosciences.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Pain, fatigue, and depression are 1 cluster of symptoms afflicting 1 in 13 survivors of prostate cancer, according to a recent study.

Post hoc data from 2 late-stage studies about siponimod, sold as Mayzent by Novartis, illustrated improved cognitive processing speed and delayed time to disability in multiple sclerosis.

The assessment of chronic obstructive pulmonary disease (COPD) now allows for the evaluation of various patient-reported outcomes (PROs); however, these PROs assess different disease features than exercise test outcomes.

Researchers provided an overview of what they deem a hopeful future for spinal muscular atrophy and Duchenne muscular dystrophy.

Reports of Medicare Advantage (MA) patients receiving higher-quality care for their cardiovascular disease prompted this comparison study of patients with heart failure enrolled in Medicare fee-for-service plans (FFS) and MA plans.

A minority of patients with multiple sclerosis (MS) have primary progressive disease, and it has few treatment options.

Patients with chronic lymphocytic leukemia (CLL) have worse health-related quality of life scores compared to healthy controls, according to a new study out of India.

A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate response to anti–tumor necrosis factor therapies.

As rare disease registries to assess orphan drugs are mainly established by the pharmaceutical industry, researchers argued post-marketing registries, functioning as marketing tools, have an underestimated influence on clinical practice.

Many patients with secondary progressive multiple sclerosis (SPMS) are actually being misclassified and treated as if they have relapsing-remitting MS (RRMS), which can have an impact on research, treatment, and health care planning, said Jan Hillert, MD, PhD, professor and senior physician at Karolinska Institutet.

Results of a combined training program in 17 patients with multiple sclerosis indicate patients reap benefits from daily activities like walking or sitting-to-standing, and show the program reduces the dual-task cost of performing cognitive tasks while walking.

The analysis, which was released on the first day of the meeting, was one of many that tried to demonstrate that earlier treatment in newly diagnosed and younger patients may forestall disease progression and disability.

Understanding each patient's individual story is vital in the transition to patient-centered care. Additionally, matching patients with physicians of the same race and background can boost comfortability among patients.

Study results show that among premenopausal women, adulthood second primary breast cancer may carry with it a 2-fold greater risk of death if they had undergone radiation treatment for cancer as a child or young adult.

There is a push to diagnose multiple sclerosis (MS) earlier, which can lead to misdiagnosis if the diagnostic criteria aren’t used properly, explained Patricia K. Coyle, MD, director of the MS Comprehensive Care Center and professor of neurology at Stony Brook University Neurosciences Institute.

Karen Kobelski is the vice president and general manager of clinical surveillance, compliance & data solutions at Wolters Kluwer. She brings more than 25 years of experience to her position, which expands her previous leadership role over the Safety & Surveillance group to also include the Health Language portfolio of data normalization solutions.

Exercise was identified as a potential intervention to improve quality of life and heighten immune response among patients with Parkinson disease.

A trial investigating an experimental treatment for patients with cancer, coronavirus disease 2019 (COVID-19) begins; new research outlines COVID-19 risks for young adults; federal regulators issue OSHA fine.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Patients with spinal muscular atrophy (SMA) incur significant health care resource utilization and cost burden, particularly those with infantile-onset SMA.

These results show that people living with HIV may not be at greater risk of contracting coronavirus disease 2019 (COVID-19) despite being immunocompromised.

This week, the top managed care news included identification of insomnia as a risk factor for type 2 diabetes; a look at the growth of telehealth during COVID-19; an overview of the speakers who will appear at Patient-Centered Oncology Care 2020.

A new study suggests stringent complete response is less meaningful than minimal residual disease status when evaluating patients with multiple myeloma.